Allogene Historical Financial Ratios
| ALLO Stock | USD 1.89 0.18 8.70% |
Allogene Therapeutics is presently reporting on over 93 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 1.03 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Allogene Therapeutics financial condition quickly.
Allogene |
About Allogene Financial Ratios Analysis
Allogene TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Allogene Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Allogene financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Allogene Therapeutics history.
Allogene Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Allogene Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Allogene Therapeutics sales, a figure that is much harder to manipulate than other Allogene Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Invested Capital
Invested capital represents the total cash investment that shareholders and debt holders have contributed to Allogene Therapeutics. There are two different methods for calculating Allogene Therapeutics invested capital: operating approach and financing approach. Understanding Allogene Therapeutics invested capital allows investors to calculate measures of performance such as return on invested capital or return on capital employed.Ev To Sales
The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.Capex To Revenue
The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.Most ratios from Allogene Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Allogene Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.At this time, Allogene Therapeutics' Price Earnings To Growth Ratio is very stable compared to the past year. As of the 18th of December 2024, Ebt Per Ebit is likely to grow to 1.10, while Book Value Per Share is likely to drop 3.10.
| 2010 | 2023 | 2024 (projected) | Interest Debt Per Share | 0.12 | 0.1 | 0.096 | Revenue Per Share | 0.28 | 6.05E-4 | 5.75E-4 |
Allogene Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Allogene Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Allogene Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 4.17 | 2.81 | 2.21 | 1.35 | 0.98 | 1.03 | |
| Book Value Per Share | 6.22 | 8.97 | 6.75 | 4.65 | 3.26 | 3.1 | |
| Free Cash Flow Yield | (0.0717) | (0.0596) | (0.1) | (0.25) | (0.47) | (0.45) | |
| Capex To Depreciation | 10.1 | 8.69 | 2.05 | 0.36 | 0.11 | 0.1 | |
| Pb Ratio | 4.17 | 2.81 | 2.21 | 1.35 | 0.98 | 1.03 | |
| Inventory Turnover | (0.0828) | (0.0558) | (0.65) | (0.27) | (0.31) | (0.32) | |
| Net Income Per Share | (1.83) | (1.94) | (1.8) | (2.3) | (2.09) | (2.19) | |
| Days Of Inventory On Hand | (4.4K) | (6.5K) | (559.33) | (1.4K) | (1.2K) | (1.3K) | |
| Payables Turnover | 0.54 | 1.11 | 1.27 | 1.2 | 41.19 | 43.25 | |
| Cash Per Share | 9.34 | 13.93 | 8.05 | 7.21 | 2.86 | 2.72 | |
| Pocfratio | (19.12) | (26.4) | (10.96) | (4.08) | (2.12) | (2.22) | |
| Capex To Operating Cash Flow | (0.37) | (0.57) | (0.12) | (0.0235) | (0.006377) | (0.006696) | |
| Pfcf Ratio | (13.96) | (16.78) | (9.82) | (3.99) | (2.11) | (2.21) | |
| Days Payables Outstanding | 671.62 | 328.6 | 286.5 | 303.08 | 8.86 | 8.42 | |
| Income Quality | 0.74 | 0.46 | 0.72 | 0.66 | 0.73 | 0.47 | |
| Roe | (0.29) | (0.22) | (0.27) | (0.5) | (0.64) | (0.67) | |
| Ev To Operating Cash Flow | (15.2) | (17.9) | (6.96) | (1.9) | (2.17) | (2.28) | |
| Pe Ratio | (14.22) | (13.01) | (8.28) | (2.73) | (1.54) | (1.62) | |
| Return On Tangible Assets | (0.26) | (0.19) | (0.24) | (0.4) | (0.51) | (0.53) | |
| Ev To Free Cash Flow | (11.1) | (11.38) | (6.24) | (1.86) | (2.16) | (2.26) | |
| Earnings Yield | (0.0703) | (0.0768) | (0.12) | (0.37) | (0.65) | (0.62) | |
| Net Debt To E B I T D A | 2.99 | 3.9 | 4.36 | 1.5 | (0.0398) | (0.0379) | |
| Current Ratio | 16.46 | 8.96 | 16.8 | 9.7 | 12.38 | 14.71 | |
| Tangible Book Value Per Share | 6.22 | 8.97 | 6.75 | 4.65 | 3.26 | 3.1 | |
| Graham Number | 15.99 | 19.78 | 16.54 | 15.53 | 12.38 | 22.54 | |
| Shareholders Equity Per Share | 6.22 | 8.97 | 6.75 | 4.65 | 3.26 | 3.1 | |
| Capex Per Share | 0.5 | 0.55 | 0.16 | 0.0363 | 0.00966 | 0.009177 | |
| Graham Net Net | 8.18 | 11.84 | 7.08 | 5.93 | 2.03 | 1.93 | |
| Enterprise Value Over E B I T D A | (11.61) | (8.21) | (7.58) | (1.3) | (1.72) | (1.63) | |
| Price Earnings Ratio | (14.22) | (13.01) | (8.28) | (2.73) | (1.54) | (1.62) | |
| Price Book Value Ratio | 4.17 | 2.81 | 2.21 | 1.35 | 0.98 | 1.03 | |
| Days Of Payables Outstanding | 671.62 | 328.6 | 286.5 | 303.08 | 8.86 | 8.42 | |
| Price To Operating Cash Flows Ratio | (19.12) | (26.4) | (10.96) | (4.08) | (2.12) | (2.22) | |
| Price To Free Cash Flows Ratio | (13.96) | (16.78) | (9.82) | (3.99) | (2.11) | (2.21) | |
| Effective Tax Rate | 0.00179 | 0.0669 | 0.0473 | 0.008469 | 0.007622 | 0.007241 |
Pair Trading with Allogene Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Allogene Stock
Moving against Allogene Stock
| 0.66 | DYAI | Dyadic International | PairCorr |
| 0.52 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
| 0.51 | BMY | Bristol Myers Squibb | PairCorr |
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Quarterly Revenue Growth (0.27) | Return On Assets (0.26) | Return On Equity (0.54) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.